Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Bibliographic Details
Main Authors:	Hugosson, J, Lilja, H, Lodding, P, Pihl, C
Format:	Journal article
Language:	English
Published:	2001

Similar Items

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
by: Zackrisson, B, et al.
Published: (2004)

Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
by: Jeeyapant, A, et al.
Published: (2017)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Biomarkers and surrogate endpoints.
by: Aronson, J
Published: (2005)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
by: Aus, G, et al.
Published: (2007)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
by: Hugosson, J, et al.
Published: (2010)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
by: Hugosson, J, et al.
Published: (2000)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
by: Aus, G, et al.
Published: (2003)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions
by: Aronson, J
Published: (2008)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
by: Lassere, M, et al.
Published: (2007)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
by: Manyara, AM, et al.
Published: (2022)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes
by: Mackay, M, et al.
Published: (2019)

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
by: Lassere, M, et al.
Published: (2007)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
by: Ciani, O, et al.
Published: (2023)

Prediction of tumor heterogeneity in localized prostate cancer.
by: Huland, H, et al.
Published: (2002)

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
by: Inker, LA, et al.
Published: (2023)

Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
by: Naesens, M, et al.
Published: (2022)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

Lead time associated with screening for prostate cancer.
by: Törnblom, M, et al.
Published: (2004)

Tumor markers in prostate cancer I: blood-based markers.
by: Shariat, S, et al.
Published: (2011)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
by: Bruun, L, et al.
Published: (2005)

Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint.
by: Sooriakumaran, P, et al.
Published: (2012)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
by: Evans, C, et al.
Published: (2009)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
by: Bergdahl, A, et al.
Published: (2009)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Deep Learning MRI-based Model for Prediction of Clinically Significant Prostate Cancer
by: Yang, Janice
Published: (2023)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Prostate volume and its correlation with histopathological outcomes in prostate cancer.
by: Sooriakumaran, P, et al.
Published: (2011)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
by: Aus, G, et al.
Published: (2005)